GlaxoSmithKline
One more brand of pills withdrawn over health risk
Greece's National Organisation for Medicines (EOF) announced it is recalling yet two more lines of an over-the-counter heartburn medication containing the drug ranitidine, over fears that production lines have been contaminated with the potential carcinogen N-nitrosodimethylamine, or NDMA.
- Read more about One more brand of pills withdrawn over health risk
- Log in to post comments
Popular heartburn pills withdrawn
Greece's EOF drug safety authority has recalled two widely used stomach acid blockers on the recommendation of the European and American authorities after laboratory tests found them to contain the potentially dangerous chemical NDMA (N-Nitroso-dimethylamine).
- Read more about Popular heartburn pills withdrawn
- Log in to post comments
Novartis sells stake in joint venture to GSK for $13 bln
Swiss pharmaceuticals giant Novartis announced on March 27 it will sell its stake in its consumer healthcare joint venture to Britain's GlaxoSmithKline for $13 billion (10.4 billion euros).
World's first malaria vaccine gets go-ahead from EU regulators
The world?s first malaria vaccine got a green light on July 24 from European drugs regulators who recommended it should be licensed for use in babies in Africa at risk of the mosquito-borne disease.
Generic drug brands allowed in prescriptions
Doctors are now being allowed to recommend specific generic drugs when they issue prescriptions, in what the government says is a move designed to increase the use of this form of medicines in Greece.
- Read more about Generic drug brands allowed in prescriptions
- Log in to post comments
Glaxo in $350 million cancer deal with biotech specialist
British pharmaceuticals giant GlaxoSmithKline has agreed a $350-million deal with Adaptimmune to help develop and sell the biotechnology firm's cancer drugs, the companies said on Monday.